Skip to main content
Premium Trial:

Request an Annual Quote

Phylos, Upstate To Develop New Protein Array Reagents

NEW YORK, June 5-The combinatorial biology company Phylos is working with Upstate, Inc to develop binding protein reagents for a new protein chip, the company said today.

 

In this arrangement, Upstate will market the chip. Phylos will receive research funding and milestone payments and royalties, if applicable.

 

Upstate, based in Waltham, Mass., develops drug discovery reagents, kits, and services based on cell signaling. It has kits for kinase activity screening and for Luminex's detection system.

 

Phylos is developing protein libraries for research into binding proteins, tissue proteomics, and therapeutics. The company is based in Lexington, Mass.

 

For further information, see the company press release.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.